ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ PHÁC ĐỒ PACLITAXEL – CARBOPLATIN TRÊN BỆNH NHÂN UNG THƯ BIỂU MÔ TUYẾN ỨC GIAI ĐOẠN IV KHÔNG CÒN KHẢ NĂNG PHẪU THUẬT

Abstract

Objectives: Evaluate the response rate, survival time and some adverse effects of the Paclitaxel - Carboplatin regimen in the treatment of patients with stage IV thymic carcinoma ineligible for surgery. Patients and method: A descriptive retrospective study involving 39 patients with stage IV thymic epithelial cancer, who were no longer surgical candidates, treated with the paclitaxel-carboplatin regimen at Hospital K from January 2018 to August 2023. Results: The partial response rate was 61.5%, the stable disease rate was 33.3%. No patient achieved complete response. The median progression-free survival and overall survival were 8.5 months and 22.5 months, respectively. The most common hematologic toxicities were anemia (74.3%) and leukopenia (69.2%). The most common non-hematological toxicities were peripheral neurotoxicity (51.3%) and AST/ALT elevation (48.7%), mainly grade 1/2. Rarely reported high-altitude toxicity. No grade 4 toxicity was noted. Conclusion:. The paclitaxel – carboplatin regimen showed acceptable efficacy and toxicity in the treatment of patients with advanced thymic cancer.